REVIEW
Progress in Detection of Biomarker of Ovarian Cancer: Lysophosphatidic Acid

https://doi.org/10.1016/S1872-2040(20)60062-7Get rights and content

Abstract

Ovarian cancer is a serious threat to women's health, and its mortality rate is the highest in gynecological cancer. At present, there is a lack of effective and convenient early diagnosis techniques for ovarian cancer. Most of the patients with ovarian cancer are found in the middle and late stage, thus missing the best time for treatment. Therefore, the rapid, sensitive, economic and accurate detection of early ovarian cancer is of great significance. In recent years, lysophosphatidic acid (LPA) has been found to increase in serum in the early stage of ovarian cancer, but less in other diseases. Therefore, LPA is a promising and highly specific marker of ovarian cancer. To detect LPA, many detection techniques have been developed, and great progress has been made in this field. This paper summarizes the detection methods of LPA, and focuses on the important progress in this field in recent years. Finally, the challenges and prospects of LPA marker detection in real clinical application are also prospected.

Graphical abstract

LPA is a highly specific marker for early-stage ovarian cancer and has great prospects for clinical applications. Quantitative detection of LPA in serum can be achieved through mass spectrometry and optical methods.

  1. Download : Download high-res image (106KB)
  2. Download : Download full-size image

References (86)

  • B Szymanska et al.

    Talanta

    (2020)
  • E Minis et al.

    Eur. J. Obstet. Gynecol. Reprod. Biol: X

    (2019)
  • I Wierstra

    Adv. Cancer Res.

    (2013)
  • A Jesionowska et al.

    Anal. Biochem.

    (2014)
  • Z Zheng et al.

    Chem. Sci.

    (2018)
  • Y Zhang et al.

    Talanta

    (2016)
  • E Cifková et al.

    J. Chromatogr. A

    (2016)
  • A Triebl et al.

    J. Chromatogr. A

    (2014)
  • J M Onorato et al.

    J. Lipid Res.

    (2014)
  • Z Zhao et al.

    J. Chromatogr. B

    (2009)
  • L Shan et al.

    J. Chromatogr. B

    (2008)
  • H Ogiso et al.

    Anal. Biochem.

    (2008)
  • M Meleh et al.

    J. Chromatogr. B

    (2007)
  • T Tanaka et al.

    J. Lipid Res.

    (2004)
  • W L Holland et al.

    J. Lipid Res.

    (2003)
  • M Kumari et al.

    Cell Metab.

    (2012)
  • V Matyash et al.

    J. Lipid Res.

    (2008)
  • Y Zhao et al.

    Chinese J. Anal. Chem.

    (2020)
  • D A Siriwardane et al.

    Int. J. Pharm.

    (2020)
  • M Antonelli et al.

    Food Chem.

    (2020)
  • H C Lee et al.

    Biochem. Biophys. Res. Commun.

    (2018)
  • W S McDonald et al.

    Am. J. Clin. Pathol.

    (2018)
  • J Y Eum et al.

    J. Chromatogr. A

    (2020)
  • T Hou et al.

    J. Chromatogr. A

    (2018)
  • K Fukasawa et al.

    J. Chromatogr. A

    (2018)
  • S Aldi et al.

    Mol. Ther. Methods Clin. Dev.

    (2018)
  • C Correnti et al.

    Structure

    (2011)
  • Y J Hao et al.

    Chinese J. Anal. Chem.

    (2020)
  • I Hurjui et al.

    J. Mol. Struct.

    (2013)
  • K Noguchi et al.

    Curr. Opin. Pharmacol.

    (2009)
  • Z Shabaninejad et al.

    J. Ovarian Res.

    (2019)
  • F Bray et al.

    Cancer J. Clin.

    (2018)
  • H I Jang et al.

    Obstet. Gynecol. Sci.

    (2017)
  • L R Ruhaak et al.

    Chem. Rev.

    (2018)
  • R C Bast et al.

    Nat. Rev. Cancer

    (2009)
  • A Azvolinsky

    Nat. Med.

    (2013)
  • N S Galenkamp et al.

    Nat. Commun.

    (2018)
  • Y Xu

    Cancers

    (2019)
  • A Saadati et al.

    Anal. Methods

    (2020)
  • S I Kim et al.

    Cancers

    (2020)
  • K Jelonek et al.

    Clin. Lipidol.

    (2013)
  • Y Song et al.

    Clin. Cancer Res.

    (2009)
  • E Kipps et al.

    Nat. Rev. Cancer

    (2013)
  • Cited by (3)

    This work was supported by the National Natural Science Foundation of China (No. 21974134) and the Innovation-Driven Project of Central South University, China (No. 202045005).

    View full text